Gonorrhea has become harder to treat. The bacterium that causes it has developed resistance to nearly every antibiotic thrown at it over the past few decades, leaving doctors with fewer reliable options. Now researchers have found something that might change that: a single pill called zoliflodacin that appears to work as well as the current two-drug approach — without the injection.
The World Health Organization estimates 82.4 million new cases of gonorrhea occurred in 2020 alone. Left untreated, the infection can cause serious complications including infertility, and it increases the risk of acquiring or transmitting HIV. The real problem isn't that gonorrhea is rare — it's that the bacteria won't stop adapting. Countries like Cambodia and Vietnam have already reported concerning resistance to ceftriaxone, one of the last reliable weapons in the arsenal.
Zoliflodacin works differently than existing antibiotics. Instead of targeting the same bacterial weak points, it disrupts DNA replication by attacking a specific part of the bacteria's DNA gyrase. Lab testing showed it remains effective against strains resistant to ciprofloxacin, ceftriaxone, and azithromycin — the drugs that currently aren't working as well.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxIn a phase 3 clinical trial published in The Lancet, researchers tested the new pill against the standard treatment across 17 outpatient clinics in five countries: the USA, South Africa, Thailand, Belgium, and the Netherlands. More than 900 people participated. Those who took zoliflodacin achieved cure rates above 90% at genital sites, matching the effectiveness of the injection-plus-pill combination. Side effects were comparable to existing treatments, and no serious safety issues emerged. Importantly, the bacteria didn't develop resistance to zoliflodacin during the trial.
If the FDA approves zoliflodacin, the impact could ripple across healthcare systems. A single oral dose is easier to deliver than an injection followed by another pill — it means community clinics and smaller facilities could offer treatment without specialized equipment. It means fewer barriers for people seeking care. It means a real option for the millions of people worldwide who need it.
The medication is currently awaiting FDA review. What happens next will determine whether this becomes another tool in the fight against drug-resistant gonorrhea, or whether doctors will continue running out of options.
